Oppenheimer Maintains an 'Outperform' on Trius Therapeutics (TSRX); ICAAC Data Shows Potential Advantages

Go back to Oppenheimer Maintains an 'Outperform' on Trius Therapeutics (TSRX); ICAAC Data Shows Potential Advantages